A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
Recruiting
Observational Study
Non Small Cell Lung Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Observational
- Participants needed
- 186 (estimated)
- Sponsor
- Yongchang Zhang · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 1.Diagnosed as advanced non-small cell lung cancer
* 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation
Exclusion Criteria:
* The patient is diagnosed with small cell lung cancer
Contacts
No contact information available.